Answers are grounded in this paper and cite their sources.
Learning Objectives After completing this course, the reader will be able to: Review the key aspects of ERBB2 signal biology in normal and cancer cells.Outline available evidence for the involvement of ERBB2 signaling in different pediatric solid cancers.Describe the key challenges associated with translating molecular targeted therapies of adult cancers to pediatric patients. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com Adult oncologists and their research colleagues have “led the charge” in the war on cancer. Their efforts have generated effective new chemotherapies that target cancer causing molecular alterations. It is hoped that these successes will be repeated within the pediatric oncology community. Testing whether molecular targeted therapies of adult cancers are also effective against childhood cancers might allow the rapid introduction of these exciting new agents into the pediatric clinic. However, it is imperative that we do not introduce blindly these agents into the pediatric population. We must ensure that molecular targets in adult cancers also fulfill a number of important criteria within the pediatric disease. This review addresses the issues surrounding the identification of molecular targets in pediatric cancers by focusing on studies of the ERBB2 oncogene.
No takes yet. Share an insight, caveat, or question.
Richard J. Gilbertson (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: